Compare EQIX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQIX | REGN |
|---|---|---|
| Founded | 1998 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1B | 84.3B |
| IPO Year | 2000 | 1995 |
| Metric | EQIX | REGN |
|---|---|---|
| Price | $1,061.74 | $923.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 35 | 28 |
| Target Price | ★ $1,234.88 | $977.93 |
| AVG Volume (30 Days) | 632.8K | ★ 889.9K |
| Earning Date | 10-28-2026 | 10-30-2026 |
| Dividend Yield | ★ 2.04% | 0.42% |
| EPS Growth | ★ 61.88 | 8.19 |
| EPS | 13.96 | ★ 37.37 |
| Revenue | ★ $5,998,545,000.00 | $5,872,227,000.00 |
| Revenue This Year | $11.78 | $30.96 |
| Revenue Next Year | $11.30 | $7.28 |
| P/E Ratio | $72.68 | ★ $24.27 |
| Revenue Growth | 7.85 | ★ 20.82 |
| 52 Week Low | $720.62 | $591.52 |
| 52 Week High | $1,128.68 | $991.73 |
| Indicator | EQIX | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 65.90 |
| Support Level | $1,046.20 | $741.03 |
| Resistance Level | $1,082.17 | N/A |
| Average True Range (ATR) | 36.49 | 32.76 |
| MACD | 7.10 | 8.82 |
| Stochastic Oscillator | 96.11 | 65.40 |
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.